Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.

U.S. healthcare expenditure expanded 7.5% in 2023 to reach $4.9T, up from 4.6% a year ago, mainly driven by non-price factors ...

We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...

With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...

When individual investors are asked about investment vehicles for “innovation,” the Invesco QQQ ETF and the ARKK Innovation ...

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

The Food and Drug Administration has finalized its decision to call an end to the drug shortage of Eli Lilly's (LLY) ...

Eli Lilly and Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...